OCEAN(a)-PreEvent: A Study Assessing Olpasiran for Cardiovascular Events (H-57595)

OCEAN(a)-PreEvent: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)

This study will evaluate the effect of an investigational drug, olpasiran, on the risk for coronary heart disease death, myocardial infarction, or urgent coronary revascularization in people with elevated lipoprotein(a) [Lp(a)] who have not previously had a major cardiovascular event. Eligibility criteria include:

• Age ≥50 years
• Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis
• Lp(a)≥ 200 nmol/L during screening

For more information call Anna Tran at 713-798-3957 or email atran@bcm.edu.